FIELD: biochemistry.
SUBSTANCE: invention relates to the field of biochemistry, in particular to an antibody or its antigen-binding fragment, which specifically bind to CTLA4, its production method, as well as to a composition and a conjugate containing it. Nucleic acid encoding the above-mentioned antibody or its fragment is also presented, as well as a vector and a cell containing it. The invention also relates to the use of the above-mentioned antibody or its fragment for the production of a bispecific antibody.
EFFECT: invention is effective for the treatment of a malignant neoplasm.
60 cl, 27 dwg, 6 tbl, 9 ex
Title | Year | Author | Number |
---|---|---|---|
ANTIBODIES AGAINST CD40 AND THEIR USE | 2018 |
|
RU2796413C2 |
ANTIBODIES AGAINST TNFRSF9 AND THEIR USE | 2019 |
|
RU2812200C2 |
ANTIBODIES AGAINST OX40 AND THEIR USE | 2017 |
|
RU2783314C2 |
ANTI-PD-1 ANTIBODY AND USE THEREOF | 2017 |
|
RU2739610C1 |
ANTIBODIES TO CD38 AND COMBINATIONS WITH ANTIBODIES TO CD3 AND CD28 | 2018 |
|
RU2812910C2 |
BINDING MOLECULES SPECIFIC FOR CD73, AND METHODS OF THEIR APPLICATION | 2015 |
|
RU2730665C2 |
ANTIBODY AGENTS SPECIFIC TO HUMAN CD19, AND THEIR APPLICATIONS | 2016 |
|
RU2773317C2 |
ANTI-αvβ8 ANTIBODIES AND COMPOSITIONS AND THEIR USE | 2019 |
|
RU2812478C2 |
TRISPECIFIC BINDING PROTEINS, RELATED METHODS AND VERSIONS OF USE THEREOF | 2020 |
|
RU2822200C2 |
TRISPECIFIC BINDING PROTEINS BINDING CD38, CD28 AND CD3, AS WELL AS METHODS OF USE FOR TREATING VIRAL INFECTION | 2019 |
|
RU2820351C2 |
Authors
Dates
2022-09-06—Published
2017-09-21—Filed